Next-generation probiotics (NGPs) are a novel class of helpful bacteria that are being created to improve human health through various therapeutic uses. Their growth is powered by developments in biotechnology and microbiome research, which have deepened the understanding of microbial interactions and their possible health advantages.

NGPs are intended for specific therapeutic interventions, unlike traditional probiotics, which are mostly used for nutritional purposes. They can be designed to treat particular diseases, such as diabetes, cancer, inflammatory bowel disease, obesity, etc. However, research involving human participants is still lacking despite the fact that many NGPs exhibit significant promise for the prevention and treatment of many chronic diseases. Consequently, regulatory bodies rarely approve these microorganisms. Furthermore, several obstacles prevent their broad market acceptance, such as the requirement for suitable techniques for cultivating and preserving these oxygen-sensitive microbes.

Understanding Next-Generation Probiotics

Next-Generation Probiotics

Traditionally, probiotics have included lactic acid-producing bacteria (LAB) such as Lactobacilli, bifidobacteria, and other species, typically sourced from fermented dairy products and fecal microbiota. As understanding the gut microbiome and its functions grows, new strategies and probiotic taxa emerge. However, a significant portion of the microorganisms in the human gut remains unidentified, as many are anaerobic bacteria that are challenging to cultivate. Advances in microbiology, particularly polymerase chain reaction (PCR) targeting the 16S rRNA gene, next-generation sequencing (NGS), and bioinformatics, have recently enabled precise identification and detection of various gut bacteria that could serve as next-generation probiotics (NGPs). NGPs have more physiological advantages than standard probiotics since they produce folate, serotonin, indoles, and short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate, all of which are important for controlling the physiological phenotype of the host.

Market Overview

The global next-generation probiotics market was valued at approximately USD 168.1 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 11.2%, reaching USD 393.9 million by 2030.

key players in next-generation probiotics

Factors Influencing the Growth of Probiotics and Solutions

1. Harsh Conditions of Gut: Nucaps® is a European company based in Navarra, Spain, specializing in innovative encapsulation technology for the industrial production of Nano capsules and Bio capsules designed for bioactives and probiotics. Their patented bioavailable capsules, which are composed of natural proteins and devoid of preservatives, improve the stability, effectiveness, and protection of the active ingredients while providing personalized solutions for better bioactive performance.

2. Sensitive to Oxygen Change: Researchers from the University of Gothenburg co-isolated Faecalibacterium prausnitzii with Desulfovibrio piger to boost its growth and function. They then “trained” the oxygen-sensitive bacteria in a favorable electrochemical environment, creating more oxygen-tolerant strains. By combining bacterial training and natural symbiosis, this approach forms live biotherapeutic items that may help avoid ailments associated with lower levels of Faecalibacterium prausnitzii.

3. Commercial Scale Production: IFF has developed advanced process capabilities for producing next-generation Akkermansia muciniphila, utilizing small-scale, high-throughput, and high-information tools combined with their large-scale manufacturing expertise from lab to pilot to industrial scale. Their efforts are backed by significant team investments, state-of-the-art facilities, and certifications. According to IFF, they will comply with EU Novel Food Regulations and pursue GRAS (Generally Recognized as Safe) status in the U.S. for this product.

Health Benefits and Potential NGP Candidates

Probiotics promote individual health through various mechanisms, including modulating the immune system, supporting epithelial cell and gut barrier integrity, producing antimicrobial substances, maintaining microbiota stability, and influencing the modulation and selection of bile acids.

Proposed Next Generation of Probiotics Candidates

Techniques for Enhancing Probiotic Viability

Regulatory Aspects

In the U.S., probiotics classified as Generally Recognized as Safe (GRAS) can be sold without prior approval, but newer strains must be registered as new dietary ingredients (NDIs). The FDA requires clinical trials for therapeutic use. The EU regulations are more stringent; requiring marketing authorization, and live biotherapeutics must undergo extensive testing. Similar ideas are followed by Russia and other areas, which modify laws to incorporate next-generation probiotics (NGPs) into food and medicine systems.

Caelus Health, a European company focused on developing next-generation microbiota-based products for preventing and treating cardio-metabolic diseases, particularly Type 2 diabetes and liver disorders, recently received a “No Questions Letter” from the U.S. Food and Drug Administration (FDA). This letter pertains to their Generally Recognized As Safe (GRAS) notice for A. soehngenii (formerly known as E. hallii), confirming its safety for use.

Current Innovations

Key Players and Their Innovations

A few of the key active companies on next-generation probiotics and their technologies are presented below:

Clinical Trials

Conclusion

In conclusion, next-generation probiotics (NGPs) mark a substantial advanced strategy for utilizing the positive effects of microbes on human health. These cutting-edge probiotics are designed for certain medical uses, focusing on long-term conditions like diabetes, obesity, and gastrointestinal issues. Overcoming obstacles to market adoption will require developing sophisticated methods for cultivating and stabilizing these microbes. The potential of NGPs to transform therapeutic interventions will become more apparent as research advances and more human studies are carried out, providing new opportunities to improve quality of life and health outcomes.